Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Equity Average (2022 - 2025)

Axsome Therapeutics' Equity Average history spans 4 years, with the latest figure at $81.0 million for Q4 2025.

  • For Q4 2025, Equity Average rose 8.08% year-over-year to $81.0 million; the TTM value through Dec 2025 reached $81.0 million, up 8.08%, while the annual FY2025 figure was $72.7 million, 41.41% down from the prior year.
  • Equity Average for Q4 2025 was $81.0 million at Axsome Therapeutics, up from $73.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $274.2 million in Q3 2023 and bottomed at $14.9 million in Q2 2022.
  • The 4-year median for Equity Average is $97.9 million (2024), against an average of $118.8 million.
  • The largest annual shift saw Equity Average soared 1206.54% in 2023 before it crashed 67.44% in 2024.
  • A 4-year view of Equity Average shows it stood at $133.5 million in 2022, then surged by 72.52% to $230.2 million in 2023, then plummeted by 67.44% to $75.0 million in 2024, then rose by 8.08% to $81.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Equity Average are $81.0 million (Q4 2025), $73.4 million (Q3 2025), and $63.1 million (Q2 2025).